Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C03 DIURETICS
C03D ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS
C03DA Aldosterone antagonists
C03DA05 Finerenone
D10633 Finerenone (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Cardiovascular Agents
Mineralocorticoid Receptor Antagonist
Finerenone
D10633 Finerenone (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
219 Miscellaneous
2190 Miscellaneous
D10633 Finerenone (JAN/USAN/INN)
Drug groups [BR:br08330]
Cardiovascular agent
DG03231 Antihypertensive
DG01676 Aldosterone antagonist
D10633 Finerenone
DG01885 Potassium-sparing diuretic
D10633 Finerenone
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
D10633 Finerenone
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D10633 Finerenone
Drug classes [BR:br08332]
Cardiovascular agent
DG01676 Aldosterone antagonist
D10633 Finerenone
DG03231 Antihypertensive
D10633 Finerenone
Target-based classification of drugs [BR:br08310]
Nuclear receptors
Estrogen like receptors
3-Ketosteroid receptor
NR3C2 (MR)
D10633 Finerenone (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10633
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10633
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10633
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10633
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10633